This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Atomoxetine for ADHD - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001
Authors' objectives
To summarise the current research evidence on atomoxetine for attention deficit hyperactivity disorder (ADHD).
Authors' conclusions
- Clinical impact: There is likely to be a significant clinical impact from the introduction of atomoxetine due to the fact that it will be the first non-stimulant drug therapy licensed for the treatment of ADHD.
- Service impact: Although there is unlikely to be a significant service impact with the introduction of atomoxetine for people already receiving specialist care for ADHD, there may be a return of parents and children with ADHD who were reluctant to accept the use of current stimulant drugs.
- Patient issues: The non-stimulant nature of atomoxetine will generate interest from patients and their carers and because of its once or twice daily dose there will be no need for a dose to be taken during the school day.
- Financial and overall NHS impact: It is difficult to estimate the likely financial impact of introducing atomoxetine for ADHD at this time, but it may be significant if it costs more than the relatively cheap alternatives and if it draws more patients into specialist care.
Attention Deficit Disorder with Hyperactivity /drug therapy; Child
Language Published
English
Country of organisation
England
English summary
An English language summary is available.
Address for correspondence
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269 Email: c.packer@bham.ac.uk